Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
781-800 of 1,694 trials

Non-Functioning Pituitary Adenomas: Cabergoline Treatment

We are studying the effects of cabergoline on non-functioning pituitary adenomas. This trial aims to see if this medication can improve treatment outcomes for patients.

Non-functioning Pituitary Adenoma>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyOncology

Bone Health: Alendronate Discontinuation Study

We are investigating the effects of stopping alendronate on fracture risk in patients with osteoporosis. The study also looks at whether specific health factors can predict bone loss after discontinuation.

Osteoporosis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineOtolaryngology

Venous Malformations: Enalapril Study

We are testing the medication enalapril in adults with painful venous malformations to see if it helps reduce pain and improve quality of life. We will also look at any changes in the size of the malformations.

Venous Malformation>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOrthopedics and Traumatology

Metastatic Colorectal Cancer: Personalized Treatment Study

We are investigating whether tailored therapies based on genetic testing can improve treatment outcomes for patients with metastatic colorectal cancer. This study aims to assess the effectiveness and safety of these new treatment options.

Metastatic Colorectal CancerEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Breast Cancer: Personalized Treatment with Capivasertib

We are studying a new treatment combining capivasertib with letrozole for women with hormone receptor positive breast cancer. This trial aims to see if this approach improves survival compared to standard treatment.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Metastatic Squamous Non-Small Cell Lung Cancer: Pembrolizumab Study

We are studying the effects of pembrolizumab alone or with MK-2870 in patients with metastatic squamous non-small cell lung cancer. The goal is to see which treatment may improve survival and quality of life.

Squamous Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Chronic Lymphocytic Leukemia: Acalabrutinib Treatment Study

We are investigating whether acalabrutinib is safe and effective for adults with chronic lymphocytic leukemia and heart problems. This study compares it to other treatment options available for these patients.

Chronic Lymphocytic Leukaemia with Cardiac Impairment>2 yearsMonitoring phase (IV)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyHematology

Systemic Lupus Erythematosus: Rapcabtagene Autoleucel Study

We are studying a new treatment for people with difficult-to-treat kidney disease caused by systemic lupus erythematosus. The goal is to see if it works better than standard care in improving kidney health.

Systemic Lupus Erythematosus with Lupus Nephritis1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNephrologyRheumatology

Early Breast Cancer: Abemaciclib and Giredestrant Study

We are investigating the safety and effectiveness of two medications for patients with early-stage, hormone-sensitive breast cancer before surgery. The goal is to see if this treatment can help reduce tumor size and improve outcomes.

Early Breast Cancer (ER-positive, HER2-negative)6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Myelodysplastic Syndromes: Ivosidenib vs. Azacitidine

We are studying the effects of a new drug, ivosidenib, in adults with myelodysplastic syndromes who have an IDH1 mutation. The goal is to understand its effectiveness and safety compared to azacitidine.

Myelodysplastic Syndrome (MDS)Hypomethylating Agent Naive Myelodysplastic Syndromes>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Thyroid Eye Disease: Sirolimus vs. Corticosteroids

We are comparing a new treatment called Sirolimus with corticosteroids for people with active thyroid eye disease. The goal is to see if Sirolimus is more effective and has fewer side effects.

Thyroid Eye Disease≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyOphthalmology

Overactive Bladder in Children: BeDry Study

We are testing solifenacin, mirabegron, and their combination for treating daytime urinary incontinence in children aged 5 to 14. The study aims to see how well these treatments work and their effects on safety and quality of life.

Daytime Urinary Incontinence3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesPediatricsUrology

Acute Agitation: Comparing New Medications

We are studying how well sublingual dexmedetomidine and buccal midazolam work for calming patients in emergency settings compared to oral lorazepam. We also want to know about their safety and how satisfied patients feel with these treatments.

Acute Agitation>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesPsychiatry

Advanced Lung Cancer: STX-241 Study

We are testing a new oral anticancer drug, STX-241, for patients with advanced non-small cell lung cancer resistant to standard treatments. The goal is to evaluate its safety and potential effectiveness.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Takotsubo Syndrome: Beta-Blockers Study

We are investigating whether beta-blockers can help improve heart function in patients with Takotsubo Syndrome. This study will also look at various heart health measures and quality of life.

Takotsubo Syndrome1-2 yearsMonitoring phase (IV)6-10 visitsPartially RemoteCardiologyInternal Medicine

BCR/ABL1-Like Acute Lymphoblastic Leukemia: Ponatinib and Chemotherapy

We are studying a new treatment combining ponatinib and chemotherapy for adults with BCR/ABL1-like acute lymphoblastic leukemia. The aim is to improve remission rates and monitor disease response over time.

Acute Lymphoblastic LeukemiaEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Behçet's Syndrome: Steroids Plus Anticoagulants Study

We are investigating whether adding anticoagulants to steroid therapy helps reduce the risk of deep venous thrombosis relapse in people with Behçet's syndrome. This study will also look at safety and quality of life.

Behcet's Syndrome>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesHematologyInternal MedicineRheumatology

Solid Tumors: E7386 with Other Anticancer Drugs

We are studying the safety and effectiveness of E7386 combined with other anticancer treatments for patients with solid tumors. This trial aims to find the best dose and assess how well it works compared to standard therapies.

Liver Cancer (Hepatocellular Carcinoma)Colorectal CancerEndometrial CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Oral Midazolam for Patients Refusing Care

We are studying whether oral midazolam can help older patients with moderate to severe cognitive disorders accept necessary care. The trial also looks at its safety and the satisfaction of healthcare providers.

Cognitive Issues and Agitation in the Elderly>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyPsychiatry

Niemann-Pick Disease Type C: N-Acetyl-L-Leucine Study

We are investigating whether N-Acetyl-L-Leucine can improve symptoms and quality of life for individuals with Niemann-Pick disease type C. The study also looks at the safety of this treatment for both older and younger patients.

Niemann-Pick Disease Type C3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteHematologyNeurology